Table 2.

Summary of the most commonly reported adverse events by grade

CP-870,893 dose cohort
0.1 mg/kg (n = 3)0.2 mg/kg (n = 6)MTD expansion 0.2 mg/kg (n = 13)
Grade 1 or 2Grade 3 or 4Grade 1 or 2Grade 3 or 4Grade 1 or 2Grade 3 or 4
Adverse eventsn (%)n (%)n (%)n (%)n (%)n (%)
Clinical events
 CRS2 (67)1 (33)6 (100)0 (0)11 (85)0 (0)
 Fatigue3 (100)0 (0)5 (83)0 (0)11 (85)0 (0)
 Nausea3 (100)0 (0)5 (83)0 (0)10 (77)0 (0)
 Vomiting1 (33)0 (0)3 (50)0 (0)6 (46)0 (0)
 Pyrexia1 (33)0 (0)1 (17)0 (0)6 (46)0 (0)
 Peripheral edema3 (100)0 (0)2 (33)0 (0)3 (23)0 (0)
 Constipation1 (33)0 (0)3 (50)0 (0)6 (46)0 (0)
 Cerebrovascular accident0 (0)0 (0)0 (0)0 (0)0 (0)1 (8)
Hematologic events
 Anemia3 (100)0 (0)4 (67)1 (17)10 (77)2 (15)
 Lymphopenia1 (33)1 (33)4 (67)0 (0)7 (54)4 (31)
 Neutropenia2 (67)0 (0)1 (17)3 (50)3 (23)2 (15)
 Thrombocytopenia2 (67)0 (0)3 (50)0 (0)3 (23)0 (0)
Nonhematologic events
 ALT2 (67)0 (0)4 (67)0 (0)8 (62)0 (0)
 AST2 (67)0 (0)3 (50)0 (0)11 (85)0 (0)
 Alkaline Phosphatase2 (67)0 (0)5 (83)1 (17)8 (62)2 (15)
 Total bilirubin2 (67)1 (33)2 (33)1 (17)5 (38)1 (8)
 Hyperglycemia2 (67)1 (33)2 (33)4 (67)11 (85)1 (8)
 Hypocalcemia2 (67)0 (0)1 (17)0 (0)10 (77)0 (0)
Hyponatremia2 (67)0 (0)3 (50)0 (0)2 (15)2 (15)